Revvity (RVTY) AI Stock Analysis

• Market Cap: $11.33B
• Dividend Yield: 0.3%
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): 39.1
• Beta (1Y): 0.70
• Revenue Growth: 0.16%
• EPS Growth: -57.72%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 2.41
• Shares Outstanding: 120,147,285
• 10 Day Avg. Volume: 1,640,287
• 30 Day Avg. Volume: 1,294,494
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 4.68
• Price to Cash Flow (P/CF): 18.50
• P/FCF Ratio: 21.50
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 10.28
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $122.70
• Price Target Upside: 30.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

Revvity's overall score reflects financial pressures from declining revenues and profitability, which is offset by improved leverage. Technical indicators suggest bearish momentum, while a high P/E ratio indicates premium valuation. Positively, the earnings call provided optimistic guidance for future growth, contributing to a more balanced assessment, but uncertainties in the market environment and FX headwinds remain potential risks.

Positive Factors

Recurring Revenue

Revvity's core recurring revenue businesses, which make up over 80% of sales, are showing positive signals, including an increase in reagents and ImmunoDx.

Shareholder Value

Solid free cash flow conversion with a likely continuation of active share buybacks suggests financial strength and shareholder value focus.

Negative Factors

External Risks

Investors are concerned about potential headwinds from China's volume-based procurement and slower recovery in the core business.

Market Guidance

The 2025 organizational growth guidance of 3-5% assumes no change to the current market environment, which is slightly below the consensus of approximately 5%.

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Revvity generates revenue primarily through the sale of its software solutions, which are marketed to businesses seeking to streamline their operations and improve efficiency. The company offers subscription-based services, providing a steady stream of recurring income. Additionally, Revvity may engage in strategic partnerships with other technology firms to expand its market reach and enhance product offerings, further contributing to its revenue growth. The company's focus on innovation ensures it remains competitive in the fast-paced technology sector, attracting a broad customer base.

Revvity Financial Statement Overview

Summary

Revvity's financial performance shows declining revenues and profitability, with a significant drop in net profit margins from 18.6% in 2021 to 9.8% in 2024. While leverage has improved with a decreasing debt-to-equity ratio, cash flow efficiency has diminished. Overall, financial stresses are evident, but a stronger equity position provides some stability.

Income Statement

Revvity's income statement shows a decline in revenue from $5.07 billion in 2021 to $2.75 billion in 2024, indicating a significant revenue contraction. Gross profit margins have remained relatively stable, at around 55.8% in 2024, which suggests efficient cost management. However, net profit margin has declined sharply from 18.6% in 2021 to 9.8% in 2024, reflecting reduced profitability. The EBIT and EBITDA margins also decreased, highlighting operational challenges.

Balance Sheet

The balance sheet reveals a decreasing debt-to-equity ratio, from 0.73 in 2020 to 0.43 in 2024, indicating improved leverage. Stockholders' equity has remained stable, while total assets have decreased. ROE, at 3.5% in 2024, has decreased over the years, suggesting less efficient use of equity. The equity ratio has increased, reflecting a stronger equity position.

Cash Flow

Revvity's cash flow analysis shows fluctuating free cash flow with a significant decline in free cash flow from $1.31 billion in 2021 to $578 million in 2024. Operating cash flow has improved to $665 million in 2024, indicating better cash generation capabilities. However, the free cash flow to net income ratio reflects reduced efficiency in converting net income to cash.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.76B	2.75B	3.31B	5.07B	3.78B
	Gross Profit
1.54B	1.54B	1.99B	2.85B	2.11B
	EBIT
346.74M	300.56M	742.70M	1.33B	978.58M
	EBITDA
848.01M	713.56M	1.30B	1.73B	1.20B
	Net Income Common Stockholders
270.38M	693.09M	569.18M	943.16M	727.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.16B	1.60B	454.36M	618.32M	402.04M
	Total Assets
12.39B	13.56B	14.13B	15.02B	8.01B
	Total Debt
3.30B	4.07B	4.56B	5.17B	2.18B
	Net Debt
2.14B	3.15B	4.11B	4.55B	1.78B
	Total Liabilities
4.73B	5.69B	6.73B	7.89B	4.27B
	Stockholders Equity
7.67B	7.87B	7.39B	7.13B	3.74B
Cash Flow		Free Cash Flow
541.65M	9.90M	594.18M	1.31B	814.67M
	Operating Cash Flow
628.30M	91.27M	679.81M	1.41B	892.18M
	Investing Cash Flow
776.16M	1.31B	-132.85M	-4.11B	-504.50M
	Financing Cash Flow
-1.13B	-947.12M	-661.80M	2.94B	-202.87M

Revvity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 94.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Negative. The current price of 94.29 is below the 20-day moving average (MA) of 96.90, below the 50-day MA of 105.84, and below the 200-day MA of 115.22, indicating a bearish trend. The MACD of -3.92 indicates Negative momentum. The RSI at 42.38 is Neutral, neither overbought nor oversold. The STOCH value of 54.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	79 Outperform	$19.40B	21.96	13.35%	1.73%	9.38%	6.43%
QGEN	74 Outperform	$9.09B	113.24	2.27%	―	0.66%	-75.89%
MEDP	69 Neutral	$8.58B	22.78	65.82%	―	9.87%	32.81%
NTRA	68 Neutral	$20.79B	―	-19.42%	―	56.75%	59.77%
RVTY	56 Neutral	$11.33B	39.15	3.64%	0.30%	0.16%	-57.72%
Sector *	51 Neutral	$5.31B	3.39	-40.42%	2.90%	18.11%	2.25%
ILMN	51 Neutral	$12.24B	―	-30.11%	―	-2.93%	-4.69%

Revvity Corporate Events

Revvity to Announce Q4 and Full-Year 2024 Results

Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.